Consider the following medical report that includes the patient's historical health records. Use it to predict the disease that the patient is high likely exposed to. 

 Medical Report: allergies: penicillins / tetracycline / cipro cystitis / benadryl decongestant / motrin / zofran / prochlorperazine maleate attending: chief complaint: oxaliplatin desensitization major surgical or invasive procedure: none history of present illness: 59f with initial high risk pt3n2bmx kras/braf-wt colon cancer s/p resection and adjuvant folfox who developed metastatic recurrence and is now s/p c15 folfiri-avastin followed by 7 cycles cetuximab-irinotecan who developed progressive disease and is now on third line oxaliplatin/capecitabine therapy. was admitted a weeek ago for oxaliplatin reaction during her c2d1 oxaliplatin infusion. on first day of oxaliplatin, she vomited four times once home and felt nauseated, but improved overnight with sleep. on c2d1, within a few minutes of beginning her oxaliplatin, she developed nausea. the oxaliplatin was stopped and then restarted. with re-challenge, nausea returned and developed a diffuse maculopapular pruritic skin eruption with hives, flushing, intense itching. also developed diarrhea and tachycardia. was admitted for management of oxaliplatin reaction. she was treated with 20 mg iv dexamethasone, hydroxyzine for itching, 2 mg iv ativan, emend, and received ivf 1l. nausea was still not well controlled with emend, and patient has hx of adverse rxns to zofran and compazine. reaction was not considered to be anaphylactic in nature and patient had no respiratory symptoms or airway compromise. symptoms resolved by hospital day 2. since discharge she has resumed her capecitabine 1gm and on completed 14d on therapy. she is using lorazepam for her nausea. on arrival to the micu, patient's vs were: 983 123 101/67 23 98% ra today feeling well. notes that she has some nausea (always has nausea these days), diarrhea, pain in both knees and back, and numbness in her toes only. also feels that her legs are more swollen than usual. past medical history: past oncology history: -- when she was diagnosed with adenocarcinoma of the colon at the splenic flexure. pathology showed low-grade adenocarcinoma of the colon with 10 of 17 pericolic lymph nodes being positive in the left colon. the lesion was classified as a pt3, pn2b, pmx lesion. her pre-op cea was 1.6. -- from -- she received adjuvant chemotherapy with folfox which was complicated by severe neuropathy, minor port problems and nausea. -- she had a takedown ileostomy resection of distal and proximal ileum w/ enterostomy. -- her ct torso showed no evidence of disease. at this time her cea was 1.6 (). -- she was followed serially and on her cea had risen to 9.3. -- ct abdomen that showed 4 solid appearing lesions w/in the liver consistent w/metastatic disease. -- a liver biopsy was planned. this procedure was aborted d/t difficult sedation and another biopsy was not attempted. -- her cea had risen again to 10.5. -- colonoscopy demonstrated submucosal prominence with overlying ulceration with some slight kinking of the edges, status post biopsy, very worrisome for malignancy at 20 cm. pathology showed multiple foci of adenocarcinoma consistent with the patient's known adenocarcinoma of the colon. -- ct showed a 4cm hypodense lesion in the right lobe of the liver and a second hypodense lesion which measures 3.1cm in size. there is an exophytic 2.5cm hypodense lesion along the inferior liver margin anteriorly which is new from previous study. there is a probable new 1.8cm lesion in the right lobe of the liver. there is a probable nodular 1cm lesion anteriorly in the left lobe of the liver. -- she was seen in consultation with dr. and tentatively planned for colon resection, right lobectomy, segmental liver resection, ious, and resection of prior ileosigmoid anastomosis on . a pre-operative ct torso was done and again showed unchanged liver lesions (when compared to study), unchanged pelvic adenopathy and no new interval lesions. -- whole body pet-ct on which demonstrated pet-avid intrabdominal disease. additionally, the pet identified focal fdg uptake in the left humeral head has an suv max of 5.47, without a definite anatomic correlate. there is no cortical disruption at this site. no other abnormal fdg avidity is present in the skeleton or soft tissues. -- mri shoulder: an 8-mm lesion in the left proximal humerus, concerning for metastasis. surgery was indefinitely postponed. -- port placed and c1d1 folfiri, no avastin with cycle 1 due to recent port. -- c2d1 folfiri-avastin -- c2d15 folfiri-avastin -- c3d1 folfiri-avastin -- ct torso: no evidence of disease progression. stable liver metastases and mesenteric deposits. -- c4d1 folfiri-avastin -- c5d1 folfiri-avastin -- c6d1 folfiri-avastin -- ct torso: stable disease, no new sites -- c7d1 folfiri-avastin -- c8d1 folfiri-avastin -- c9d1 folfiri-avastin -- c10d1 folfiri-avastin -- ct torso: stable disease, no new sites -- c12d1 folfiri-avastin -- c13d1 folfiri-avastin -- admitted with buttock abscess, drained in ed -- c14d1 folfiri (avastin held for buttock wound) -- c15d1 folfiri (avastin held for buttock wound) -- ct torso with significant hepatic progression -- c1d1 cetuximab-irinotecan -- c2d1 cetuximab-irinotecan -- c2d22 admitted with volume depletion, , resolved with ivf and anti-motility agents. -- c3d1 cetuximab-irinotecan -- c4d1 cetuximab-irinotecan (d8, d15 irinotecan held for diarrhea, d22 () cetuximab held for worsening rash -- c5d1 cetuximab-irinotecan -- c5d15 held for diarrhea -- c5d22 irinotecan held, cetuximab given -- c5d28 cetuximab -- c5d36 cetuximab -- c6d1 cetuximab-irinotecan -- c7d1 cetuximab-irinotecan -- , -- chemo held for gi toxicities -- ct with interval progression and >20% increase in hepatic disease burden, no new disease sites, cea rising -- c1d1 capecitabine 1500mg po bid other pmh: 1. ovarian cysts 2. cervical dysplasia 3. osteoarthritis 4. spinal stenosis on chronic darvocet 5. torn meniscus 6. peripheral edema 7. gerd 8. s/p cck 9. stage iv colorectal cancer as above 10. mrsa r.buttock abscess, s/p i&d on , tx with clinda social history: living/support: lives alone, no children. she has many local friends. /income: works as an educational consultant and standard poodle breeder. last won a show yesterday in nh. her license plate says "poodle." tobacco: 1ppdx10yrs, quit 20yrs ago etoh: 3 glasses/month illicits: denies, no h/o ivdu family history: - mother: died at 91 of natural causes, had thyroid cancer - father: died at 68 of cva - other: no known malignancies. she has a first cousin with hemachromatosis and an aunt with several gastric surgeries (not for malignancy) physical exam: exam on admission general: alert, oriented, no acute distress heent: sclera anicteric, mmm, oropharynx clear, eomi, perrl neck: supple, jvp not elevated, no lad cv: regular rate and rhythm, normal s1 + s2, no murmurs, rubs, gallops lungs: clear to auscultation bilaterally, no wheezes, rales, ronchi. port site c/d/i. abdomen: soft, non-distended, bowel sounds present, no organomegaly, mild tenderness to palpation, no rebound or guarding, +post-op scar gu: no foley ext: warm, well perfused, 2+ pulses, 1+ edema bl lower extremity neuro: cnii-xii intact, 5/5 strength upper/lower extremities, grossly normal sensation, 2+ reflexes bilaterally, steady gait exam on discharge general: alert, oriented, no acute distress heent: sclera anicteric, mmm, oropharynx clear, eomi, perrl neck: supple, jvp not elevated, no lad cv: regular rate and rhythm, normal s1 + s2, no murmurs, rubs, gallops lungs: clear to auscultation bilaterally, no wheezes, rales, ronchi. port site c/d/i. abdomen: soft, non-distended, bowel sounds present, no organomegaly, mild tenderness to palpation, no rebound or guarding, +post-op scar gu: no foley ext: warm, well perfused, 2+ pulses, 1+ edema bl lower extremity neuro: cnii-xii intact, 5/5 strength upper/lower extremities, grossly normal sensation, 2+ reflexes bilaterally, steady gait pertinent results: 11:20am blood wbc-16.0* rbc-3.61* hgb-9.9* hct-31.0* mcv-86 mch-27.5 mchc-31.9 rdw-22.4* plt ct-327 05:23am blood glucose-131* urean-15 creat-0.4 na-138 k-4.1 cl-108 hco3-23 angap-11 11:20am blood alt-28 ast-83* ld(ldh)-1818* ck(cpk)-193 alkphos-212* totbili-2.5* dirbili-1.4* indbili-1.1 11:20am blood totprot-6.5 albumin-3.3* globuln-3.2 calcium-8.3* phos-2.3* mg-1.0* 11:20am blood cea-2206* 09:18am blood lactate-3.0* 05:38am blood lactate-1.5 ruq us: findings: as known from prior ct of , there are extensive metastatic lesions throughout the liver. the main portal vein is patent with hepatopetal flow. no intra- or extra-hepatic ductal dilatation is noted. common bile duct measures 3 mm. the patient is status post cholecystectomy. bilateral kidneys show no evidence of solid masses or hydronephrosis. spleen measures 12.3 cm, slightly increased from prior examination. impression: 1) innumerable masses in the liver consistent with metastatic disease. no evidence of biliary obstruction; patent portal vein. 2) spleen is increased slightly in size though remains upper limits of normal. cxr for port eval: findings: pa, lateral, and oblique views of the chest were obtained with the patient in the upright position. the chemotherapy port catheter is seen with the tip in the mid svc. there is no obvious break in the length of the catheter. the lungs are well expanded and clear. there are no pleural effusions or pneumothorax. there is moderate cardiomegaly. osseous structures are unremarkable. there is some upper zone redistribution pattern. there is no edema, infiltrate or other acute process identified. impression: there is no obvious break in the port catheter that can be visualized on plain film. we would recommend performing recanalization and further evaluation under fluoroscopic guidance if clinical concern remains. brief hospital course: # oxaliplatin desensitization: followed protocol per hematology/oncology service with one to one monitoring, continuous vital signs monitoring, and premedication protocol including hydroxyzine, famotidine, montelukast, and methylprednisolone. in addition, prn lorazepam was given for anxiety as well as nausea. electrolytes were aggressively repleted prior to initiation of the protocol. during initiation, patient was noted to have a fever to 101. blood cultures and urine cultures were sent, which were ultimately negative, as was a cxr, which was negative for cardiopulmonary process. there was low suspicion for infection, and was thought to be drug related. the hem/onc fellow was notified. overnight during escalation of dosing challenge, patient became acutely tachycardic to the 150s although remained normotensive. she received 50 mg iv diphenhydramine and 1 mg ativan in addition to a 1 liter fluid bolus, after which her heart rate improved. thereafter, patient was found to have a 20 beat run of wide complex ventricular tachycardia while having a bowel movement, and was again tachycardic to the 130s, for which she received another liter of fluid bolus. electrolytes were again aggressively repleted. # gerd: we continued her home omeprazole. # chronic back pain: in order to better monitor vital signs, patient's home vicodin was held in favor of oxycodone for pain control. # leukocytosis: patient presented with a leukocytosis as noted on relevant laboratory studies. this was attributed to chronic steroid use, as the patient denied constitutional symptoms. fever, discussed above, was thought to be due to drugs. however, blood culture, urine culture, and cxr were performed. # mild transaminitis: patient presented with mild transaminitis, likely secondary to chemotherapy. ruq u/s was performed which suggested that transaminitis was most likely secondary to known extensive metastatic disease and no acutely reversible cause of obstruction, inflamation, or infection. # chronic diarrhea: patient complained of chronic diarrhea. c diff dna was sent, which was negative. medications on admission: capecitabine - 500 mg tablet - 2 tablet(s) by mouth twice a day take for 14days, then stop for 7days and repeat. icd9 code: 153.9 dexamethasone - 4 mg tablet - 2 tablet(s) by mouth once a day on day 2 and 3 after chemotherapy. hydrocodone-acetaminophen - 5 mg-500 mg tablet - 1 tablet(s) by mouth q4-6hrs as needed for pain lorazepam - 0.5 mg tablet - tablet(s) by mouth q6hrs as needed for anxiety do not drive while taking this medication omeprazole - (prescribed by other provider) - 20 mg capsule,delayed release(dr/ec) - 1 capsule(s) by mouth once a day -patient also reports taking hydrochlorothiazide 50 mg prn for swelling. -says she is currently not taking lumigan but may restart. discharge medications: 1. hydrocodone-acetaminophen (5mg-500mg 1 tab po q4-6hr:prn pain 2. omeprazole 20 mg po daily 3. capecitabine 500 2 po bid per dr. (2 tablet(s) by mouth twice a day take for 14days, then stop for 7days and repeat) 4. dexamethasone 8 mg po q8h on day 2 and 3 after chemotherapy 5. lorazepam 0.5-1 mg po q6h:prn anxiety, nausea discharge disposition: home discharge diagnosis: primary: colon cancer secondary: desensitization for serious allergic reaction discharge condition: mental status: clear and coherent. level of consciousness: alert and interactive. activity status: ambulatory - independent. discharge instructions: dear mrs. , it was a pleasure to take care of you at . you were admitted for oxaliplatin treatment and desensitization. you were premedicated and continuously monitored for an adverse reaction. you are being discharged with an appointment to follow up with your oncologist, dr. , most likely on . followup instructions: please follow-up with your oncologist, dr. , who will be making an appointment for you for . if you do not hear from them within 1 day of discharge, please call the office directly. procedure: injection or infusion of cancer chemotherapeutic substance diagnoses: acidosis other chronic pain esophageal reflux malignant neoplasm of liver, secondary personal history of tobacco use need for desensitization to allergens osteoarthrosis, unspecified whether generalized or localized, site unspecified personal history of malignant neoplasm of large intestine diarrhea backache, unspecified tachycardia, unspecified secondary malignant neoplasm of bone and bone marrow secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes encounter for antineoplastic chemotherapy 

Answer: The patient is high likely exposed to